Faron Pharmaceuticals Oy (LSE:FARN) EV-to-EBIT : (As of May. 25, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Faron Pharmaceuticals Oy's Enterprise Value is £143.93 Mil. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-EBIT for today is .

The historical rank and industry rank for Faron Pharmaceuticals Oy's EV-to-EBIT or its related term are showing as below:

LSE:FARN' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.52 Med: -5.3 Max: -0.66
Current: -5.81

During the past 12 years, the highest EV-to-EBIT of Faron Pharmaceuticals Oy was -0.66. The lowest was -67.52. And the median was -5.30.

LSE:FARN's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs LSE:FARN: -5.81

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Faron Pharmaceuticals Oy's Enterprise Value for the quarter that ended in Dec. 2023 was £215.17 Mil. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Faron Pharmaceuticals Oy's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

Faron Pharmaceuticals Oy EV-to-EBIT Historical Data

The historical data trend for Faron Pharmaceuticals Oy's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy EV-to-EBIT Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-9.91

-7.97

-7.84

-7.77

-8.68

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-7.84	-	-7.77	-	-8.68

Competitive Comparison of Faron Pharmaceuticals Oy's EV-to-EBIT

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-EBIT falls into.

Faron Pharmaceuticals Oy EV-to-EBIT Calculation

Faron Pharmaceuticals Oy's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	143.926	/	0
	=

Faron Pharmaceuticals Oy's current Enterprise Value is £143.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Faron Pharmaceuticals Oy (LSE:FARN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Faron Pharmaceuticals Oy's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	0	/	215.171435
	=	%

Faron Pharmaceuticals Oy's Enterprise Value for the quarter that ended in Dec. 2023 was £215.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Faron Pharmaceuticals Oy EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines